Non-hydrostatic pulmonary edema after coronary artery ligation in dogs. Protective effect of indomethacin.
Pulmonary edema which develops during acute myocardial infarction is generally believed to result solely from pulmonary microvascular hypertension. However, patient with myocardial infarction and pulmonary edema occasionally are found to have normal pulmonary wedge pressure. We report data indicating that pulmonary edema develops after coronary artery ligation despite stable microvascular pressure. Four groups of open-chest dogs were studied: (1) nine dogs with left anterior descending coronary artery ligation, (2) seven dogs with sham coronary ligation, (3) seven dogs ligated after beginning an infusion of indomethacin (5 mg/kg per hr), and (4) five dogs ligated after an infusion of the drug's vehicle was begun. Extravascular lung water and pulmonary blood volume were measured at hourly intervals during the 2 hours before and after coronary ligation or sham ligation. Gravimetric lung water was measured immediately thereafter. Changes of net pulmonary intravascular driving force (the difference of microvascular hydrostatic and oncotic pressure) after ligation or sham ligation were small and comparable in all groups. Pulmonary blood volume did not change in any group. Pulmonary extravascular water volume remained constant in the sham group but rose significantly in the ligated group. Gravimetric lung water also was significantly higher in the latter group. We interpret these results to indicate that factors other than microvascular pressure can mediate the formation of these results to indicated that factors other than microvascular pressure can mediate the formation of edema during acute myocardial infarction; increased pulmonary microvascular permeability may be responsible. Indomethacin infusion blocked the formation of edema after coronary ligation, even though net microvascular driving force was highest in this group. Infusion of the vehicle alone did not prevent edema. The mechanism by which indomethacin exerts this protective effect is unclear but is probably a result of its inhibition of cyclo-oxygenase or cyclic nucleotide phosphodiesterase.
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000150:complications; D001794:Blood Pressure; D001834:Body Water / Q000032:analysis; D002302:Cardiac Output; D003331:Coronary Vessels / Q000503:physiopathology*; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D006874:Hydrostatic Pressure; D007213:Indomethacin / Q000494:pharmacology / Q000627:therapeutic use*; D008026:Ligation; D008168:Lung / Q000503:physiopathology; D008176:Lung Volume Measurements; D011312:Pressure; D011654:Pulmonary Edema / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology
D007213:Indomethacin